Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Humacyte Inc.
Headquarters: Research Triangle Park, NC, United States of America
Website: http://www.humacyte.com
Year Founded: 2004
Status: Public
Industry Sector: HealthTechnology
CEO: Laura E. Niklason, MD, PhD
Number Of Employees: 220
Enterprise Value: $633,729,440
PE Ratio: -1.15
Exchange/Ticker 1: NASDAQ:HUMA
Exchange/Ticker 2: N/A
Latest Market Cap: $224,922,608
BioCentury | Jul 16, 2024
Deals
Deals report: Ipsen gets second ADC; Context buys MSLN
Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships
BioCentury | Mar 9, 2023
Management Tracks
Biogen taps Dorsa to succeed Papadopoulos as chair
Plus: new chair at Venatorx, and updates from VarmX and Nutcracker
BioCentury | Sep 21, 2022
Management Tracks
New CEOs at Scholar Rock, Neuway, NeuVasQ and ProLynx
Plus Serono’s Maria Rivas joins Pfizer, and updates from
BioCentury | Aug 27, 2021
Deals
Aug. 26 Quick Takes: Bolt, Innovent partner on non-traditional antibody conjugates
Plus ADC royalty deal, Sobi, Servier, DiCE IPO plans, AZ in Wilson’s and more
BioCentury | Aug 18, 2021
Management Tracks
Smith named CEO at Remix
Plus: Jubilant, Sparrow, n-Lorem, OncXerna and more
BioCentury | Nov 25, 2020
Management Tracks
DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma
Food allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) announced that Hugh Sampson is stepping down from his role as CSO, effective Dec. 1. Sampson will remain as
BioCentury | Feb 6, 2020
Deals
Beyond Keytruda: How Merck envisions innovation and growth after a spinout
Recent and future BD will help drive Merck's innovation, while slower-growing businesses are headed for a new entity
BioCentury | Nov 23, 2019
Company News
Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more
BioCentury | Mar 9, 2019
Company News
Management tracks: Lundbeck hires first CBO; ICT opens U.S. office
BioCentury | Oct 8, 2018
Company News
Management tracks: As Akcea shifts to commercialization, Crooke resigns from board
Items per page:
1 - 10 of 26